comprehensive -WSS

comprehensive

author：focus 2025-10-01 17:19:25 - browse：67739

Adobe

WASHINGTON — The federal government increasingly is scrutinizing Chinese businesses and their interactions with American companies, including in the biotech sector. Chinese biotechnology companies, the thinking goes, could threaten national security by giving the Chinese government access to the genetic and health information of Americans.

Just Wednesday, President Biden issued an executive order aimed at keeping sensitive data, including Americans’ genetic information, out of the hands of adversaries.

But American biotech companies worry they could become collateral damage if the government sloppily targets sanctions. They’re pushing back against legislation that would bar biotech companies from working with some Chinese companies, especially as the government takes aim at WuXi, a Chinese company considered a crucial partner for discovering, testing, and making medicines that has worked with such brands as Pfizer, AstraZeneca, and GSK.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Elevance PBM president out as customers face prescription chaos

WSS

Eli Lilly’s Zepbound improved liver scarring in mid

To avoid data mishandling cases, universities eye AI and other tools

Robert F. Kennedy is pitching centrism on health, even on abortion

A new initiative will help leaders fight the next pandemic

FDA approves Moderna’s RSV vaccine, its second licensed product

PhRMA lawsuit over Medicare drug price negotiation tossed

leisure time

comprehensive

focus

How to save PrEP access — and even expand it

Readout Newsletter: Biogen, Rocket Pharma, KalVista, and more

ChatGPT in medicine: STAT answers readers' burning questions

Robert F. Kennedy is pitching centrism on health, even on abortion

Supreme Court strikes down use of affirmative action

A new initiative will help leaders fight the next pandemic

The high cost of giving birth even with insurance

Industry veterans launch new biotech VC with $310M

BioMarin wins approval for gene therapy to treat hemophilia A

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

focus

Data don't support strong claims for Covid

For Medicare Advantage, Democrats want stronger protections around AI

How digital tools helped lower hypertension in marginalized patients

Biden report: The neurospychology of memory and aging

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

What we’ve learned from the Aduhelm mess

Wikipedia

entertainment

entertainment

hotspot